Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus durvalumab in relapsed and refractory multiple myeloma progressing on daratumumab
2016-003801-32Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab and durvalumab in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Overall response rate and Progressive disease rate. Started Jan 2017; status: terminated.
02
Drugs
daratumumabdurvalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-003801-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003801-32.